TEVA PHARMACEUTICAL INDUSTRIES LIMITED Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss)
TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVA) reported Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss) of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-09.
Discontinued › Income Statement › Other Income
us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss · last filed 2022-02-09
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED fair value, asset, recurring basis, still held, unrealized gain (loss) for the quarter ending 2021-12-31 was $9.00M.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED fair value, asset, recurring basis, still held, unrealized gain (loss) for the quarter ending 2021-09-30 was $0.00.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED fair value, asset, recurring basis, still held, unrealized gain (loss) for the quarter ending 2020-12-31 was -$38.00M.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED fair value, asset, recurring basis, still held, unrealized gain (loss) for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED fair value, asset, recurring basis, still held, unrealized gain (loss) for fiscal 2020 was $80.00M.
| Period end | Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss) 3 month | Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss) 6 month | Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss) 9 month | Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2021-12-31 | $9.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $9.00M derived: sum of 2 quarters · filed 2022-02-09 | $0.00 10-K · filed 2022-02-09 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-27 | -$9.00M 10-Q · filed 2021-10-27 | ||
| 2021-06-30 | -$9.00M 10-Q · filed 2021-07-28 | |||
| 2020-12-31 | -$38.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $80.00M 10-K · filed 2022-02-09 | ||
| 2020-09-30 | $118.00M 10-Q · filed 2021-10-27 |